SCHEMBL20239148

SCHEMBL20239148

CNS(=O)(=O)Cc1ccc(Oc2cc(CN)nc(SC)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPT P10636 5/20 0.39
HTT P42858 4/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
DGAT2 Q96PD7 1/20 0.35
SMN1; SMN2 Q16637 6/20 0.34
PGR P06401 1/20 0.34
ALDH1A1 P00352 4/20 0.33
RAB9A P51151 2/20 0.33
L3MBTL1 Q9Y468 4/20 0.33
RECQL P46063 1/20 0.33
NPC1 O15118 1/20 0.33
MAPK1 P28482 2/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738671 0.87 SMN1; SMN2 (0.37) NPSR1MAPTMEN1KMT2ADGAT2
SCHEMBL20239242 0.82 LMNA (0.41) LMNATSHRNPSR1MAPTHTT
SCHEMBL20239176 0.81 DGAT2 (0.55) LMNATSHRNPSR1MAPTHTT
SCHEMBL20239300 0.77 LOXL2 (0.42) TSHRMEN1KMT2ASMN1; SMN2PGR
SCHEMBL20239318 0.74 LMNA (0.45) LMNATSHRNPSR1MAPTHTT
SCHEMBL16738665 0.74 DGAT2 (0.44) LMNATSHRNPSR1MAPTMEN1
SCHEMBL20239260 0.74 DGAT2 (0.46) LMNANPSR1MAPTMEN1KMT2A
SCHEMBL20239160 0.73 PGR (0.37) LMNAHTTSMN1; SMN2PGRALDH1A1
SCHEMBL20239299 0.73 LOXL2 (0.57)
SCHEMBL16738667 0.72 SMN1; SMN2 (0.47) MEN1KMT2ADGAT2SMN1; SMN2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT LMNA 2022/4885TSHR 777/4885NPSR1 2321/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT LMNA 1722/4885TSHR 690/4885NPSR1 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.